Pliant Therapeutics, Inc. (PLRX)
Largest Insider Buys in Sector
PLRX Stock Price History Chart
PLRX Stock Performance
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Activity of Pliant Therapeutics, Inc.
Over the last 12 months, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $4.4M worth of Pliant Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $9.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Pliant Therapeutics, Inc.
| 2024-01-17 | Sale | Coulie Bernard | President and CEO | 25,721 0.0414% | $17.23 | $443,173 | -17.89% | |
| 2024-01-17 | Sale | Cummings Keith Lamont | Chief Financial Officer | 9,781 0.0157% | $17.23 | $168,527 | -17.89% | |
| 2024-01-17 | Sale | Hull Hans | Chief Business Officer | 9,786 0.0158% | $17.23 | $168,613 | -17.89% | |
| 2024-01-17 | Sale | Lefebvre Eric | Chief Medical Officer | 10,295 0.0166% | $17.23 | $177,383 | -17.89% | |
| 2024-01-17 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 5,197 0.0084% | $17.23 | $89,544 | -17.89% | |
| 2023-08-04 | Sale | Hull Hans | Chief Business Officer | 20,050 0.0337% | $20.01 | $401,201 | -24.22% | |
| 2023-08-03 | Sale | Hull Hans | Chief Business Officer | 14,869 0.0258% | $20.00 | $297,380 | -21.49% | |
| 2023-07-20 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 4,755 0.0085% | $17.55 | $83,450 | -11.31% | |
| 2023-07-17 | Sale | Coulie Bernard | President and CEO | 70,150 0.1263% | $18.01 | $1.26M | -12.84% | |
| 2023-07-17 | Sale | Hull Hans | Chief Business Officer | 17,937 0.0323% | $18.01 | $323,029 | -12.84% | |
| 2023-07-17 | Sale | Cummings Keith Lamont | Chief Financial Officer | 19,771 0.0356% | $18.01 | $356,058 | -12.84% | |
| 2023-07-17 | Sale | Lefebvre Eric | Chief Medical Officer | 22,321 0.0402% | $18.01 | $401,981 | -12.84% | |
| 2023-07-17 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 12,778 0.023% | $18.01 | $230,120 | -12.84% | |
| 2023-04-03 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 2,877 0.0052% | $26.79 | $77,066 | -35.48% | |
| 2023-03-30 | Sale | Coulie Bernard | President and CEO | 35,339 0.063% | $26.52 | $937,222 | -35.31% | |
| 2023-03-30 | Sale | Hull Hans | Chief Business Officer | 9,036 0.0161% | $26.52 | $239,643 | -35.31% | |
| 2023-03-30 | Sale | Cummings Keith Lamont | Chief Financial Officer | 9,960 0.0178% | $26.52 | $264,148 | -35.31% | |
| 2023-03-30 | Sale | Lefebvre Eric | Chief Medical Officer | 11,245 0.02% | $26.52 | $298,228 | -35.31% | |
| 2023-03-30 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 4,874 0.0087% | $26.52 | $129,263 | -35.31% | |
| 2023-02-03 | Sale | Coulie Bernard | President and CEO | 15,000 0.0269% | $33.61 | $504,200 | -45.72% |
Institutional Investor Ownership
| Deep Track Capital Lp | $85.67M | 9.53 | 5.75M | 0% | +$0 | 0.39 | |
| BlackRock | $69.37M | 7.72 | 4.66M | -3.04% | -$2.18M | <0.01 | |
| T. Rowe Price | $58.99M | 6.56 | 3.96M | +4.57% | +$2.58M | 0.01 | |
| Fidelity Investments | $58.8M | 6.54 | 3.95M | -0.43% | -$252,122.92 | <0.01 | |
| First Light Asset Management | $52.67M | 5.86 | 3.53M | -1.58% | -$846,066.70 | 4.16 | |
| The Vanguard Group | $51.83M | 5.77 | 3.48M | +13.45% | +$6.15M | <0.01 | |
| Laurion Capital Management LP | $51.77M | 5.76 | 3.47M | -3.04% | -$1.62M | 1.45 | |
| Redmile Group | $46.15M | 5.13 | 3.1M | +14.85% | +$5.97M | 1.71 | |
| Blue Owl Capital Holdings Lp | $44.76M | 4.98 | 3M | 0% | +$0 | 8.43 | |
| Trv Gp Iv Llc | $31.78M | 3.54 | 2.13M | 0% | +$0 | 15.4 | |
| Polar Capital | $30.02M | 3.34 | 2.02M | 0% | +$0 | 0.17 | |
| Great Point Partners | $27.59M | 3.07 | 1.85M | +1.57% | +$427,332.01 | 4.62 | |
| Citadel Advisors LLC | $25.36M | 2.82 | 1.7M | +7.81% | +$1.84M | 0.02 | |
| Franklin Templeton Investments | $22.9M | 2.55 | 1.54M | -2.71% | -$636,557.86 | 0.01 | |
| Deutsche Bank | $22.14M | 2.46 | 1.49M | +50.84% | +$7.46M | 0.01 | |
| Capital International Investors | $20.52M | 2.28 | 1.38M | +50.95% | +$6.93M | <0.01 | |
| State Street | $19.65M | 2.19 | 1.32M | -1.24% | -$246,013.90 | <0.01 | |
| RA Capital Management, L.P. | $19.09M | 2.12 | 1.28M | 0% | +$0 | 0.02 | |
| Geode Capital Management | $18.1M | 2.01 | 1.21M | +2.33% | +$412,562.00 | <0.01 | |
| Granahan Investment Management | $15.6M | 1.74 | 1.05M | -9.03% | -$1.55M | 0.55 | |
| Casdin Capital | $14.9M | 1.66 | 1M | -36.59% | -$8.6M | 1.11 | |
| Candriam S C A | $8.17M | 0.91 | 548,000 | +20.97% | +$1.42M | 0.05 | |
| Bessemer Group Inc | $7.93M | 0.88 | 532,079 | 0% | +$0 | 0.01 | |
| Goldman Sachs | $7.49M | 0.83 | 502,571 | +29.78% | +$1.72M | <0.01 | |
| Bank of America | $7.42M | 0.83 | 497,814 | +535.53% | +$6.25M | <0.01 | |
| Northern Trust | $7.38M | 0.82 | 495,289 | -1.99% | -$149,551.32 | <0.01 | |
| Fernwood Investment Management Llc | $6.68M | 0.74 | 448,385 | +5.96% | +$375,599.23 | 0.31 | |
| Charles Schwab | $6.41M | 0.71 | 430,286 | +1.44% | +$90,740.99 | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $5.74M | 0.64 | 384,996 | 0% | +$0 | 0.15 | |
| Morgan Stanley | $5.72M | 0.64 | 384,102 | -5.17% | -$311,723.02 | <0.0001 | |
| Ameriprise Financial | $5.53M | 0.62 | 371,126 | +0.36% | +$19,742.50 | <0.01 | |
| UBS | $5.44M | 0.61 | 365,064 | +6.69% | +$341,075.92 | <0.01 | |
| Barclays | $5.37M | 0.6 | 360,145 | +2.05% | +$107,991.97 | <0.01 | |
| AXA | $5.17M | 0.58 | 347,194 | +0.03% | +$1,400.60 | 0.02 | |
| Dimensional Fund Advisors | $4.47M | 0.5 | 300,170 | +94.82% | +$2.18M | <0.01 | |
| Mass General Brigham Inc | $4.3M | 0.48 | 288,690 | New | +$4.3M | 7.53 | |
| Arrowmark Colorado Holdings Llc | $4.19M | 0.47 | 281,189 | 0% | +$0 | 0.01 | |
| Sphera Fund | $3.85M | 0.43 | 258,554 | +33.58% | +$968,500.10 | 0.64 | |
| Citigroup | $3.18M | 0.35 | 213,305 | +198.43% | +$2.11M | <0.01 | |
| Nuveen | $3.16M | 0.35 | 211,930 | +11.11% | +$315,790.70 | <0.01 | |
| BNY Mellon | $2.97M | 0.33 | 199,064 | -5.5% | -$172,482.19 | <0.01 | |
| Silverarc Capital Management Llc | $2.73M | 0.3 | 183,392 | -42.42% | -$2.01M | 0.81 | |
| Two Sigma Advisers LP | $2.23M | 0.25 | 149,500 | +61.45% | +$847,810.00 | <0.01 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $2.16M | 0.24 | 145,250 | +28.84% | +$484,384.10 | 0.21 | |
| Marshall Wace | $1.95M | 0.22 | 130,935 | New | +$1.95M | <0.01 | |
| Jane Street Capital | $1.92M | 0.21 | 128,912 | +44.61% | +$592,543.26 | <0.01 | |
| Td Asset Management Inc | $1.67M | 0.19 | 112,248 | 0% | +$0 | <0.01 | |
| Two Sigma | $1.59M | 0.18 | 107,024 | New | +$1.59M | <0.01 | |
| Bond Devick Financial Network Inc | $1.49M | 0.17 | 100,160 | 0% | +$0 | 0.97 | |
| Woodline Partners LP | $1.49M | 0.17 | 100,143 | -19.3% | -$356,810.37 | 0.01 |